Skip to main content

Press releases

13/10/26 - 13:00

Diasorin obtained FDA approval for Human Parvovirus B19 IgM and IgG on the Liaison XL (334.34 KB)
Products Immunodiagnostic

02/10/26 - 14:22

Margherita Sacerdoti appointed Investor Relations & ESG Senior Director at Diasorin (151.77 KB)
Other

31/07/26 - 12:50

Revenue and EBITDA Supported by Strong Q2 Growth in the First Half of the Year. 2026 Guidance Confirmed. (277.39 KB)
Financial Data

19/06/26 - 15:45

Diasorin Announces FDA 510(K) Clearance and CLIA Waiver for the LIAISON NES Group A Streptococcus (GAS) Assay (174.02 KB)
Products Molecular

20/05/26 - 11:16

Diasorin Board of Directors approves the 2026-2030 Business Plan (246.32 KB)
Financial Data

19/05/26 - 19:23

Diasorin Receives 510(K) Clearance for Fully Customizable LIAISON PLEX Gastrointestinal Flex Assay (179.61 KB)
Products Molecular

08/05/26 - 17:54

Revenues and EBITDA in line with the expected quarterly revenue trend and impacted by a weak flu season. 2026 Guidance confirmed (256.38 KB)
Financial Data

04/05/26 - 17:45

Diasorin Strengthens its Leadership of Immuno Division with the Appointment of Gabriele Allegri as President (158.42 KB)
Other

29/04/26 - 15:52

Shareholders' Meeting 2026 (166.06 KB)
Other

07/04/26 - 10:05

Communication on total amount of voting rights (7 April 2026) (225.44 KB)
Other

20/03/26 - 17:44

Revenues and EBITDA growth in line with FY 2025 Guidance. Proposed ordinary dividend per share of €1.30, +8.3% vs 2024 (349.08 KB)
Financial Data

19/03/26 - 9:47

Diasorin signs strategic distribution agreement with McKesson Medical Surgical to expand access for the LIAISON NES molecular point‑of‑care platform (234.16 KB)
Other

24/02/26 - 7:06

Diasorin introduces next-generation LIAISON QuantiFERON-TB Gold Plus II assay for the U.S. in partnership with QIAGEN (154.8 KB)
Products Immunodiagnostic

03/02/26 - 12:13

Diasorin submits LIAISON NES Group A Strep molecular test to the U.S. FDA for 510(k) Clearance and CLIA Waiver (130.94 KB)
Products Molecular

29/01/26 - 7:03

Diasorin has been granted De novo authorization in the U.S. for the First Fully Automated Laboratory Test for Hepatitis Delta Virus (HDV) on the LIAISON XL (128.56 KB)
Products Immunodiagnostic

27/01/26 - 16:05

The Shareholders' meeting authorized the purchase of treasury shares, approved the amendment of art. 5 of the articles of association and authorized the cancellation of treasury shares. The Board approved the launch of the buyback plan. (120.91 KB)
Other

26/01/26 - 7:09

Diasorin signs exclusive distribution agreement for the LIAISON NES® molecular point‑of‑care platform and the Flu A/B, RSV & Covid‑19 panel (131.63 KB)
Products Molecular

23/01/26 - 17:49

Succession in the role of Group Chief Financial Officer of Diasorin. Alberto Donati appointed new Group Chief Financial Officer. (108.99 KB)
Other

16/12/19 - 14:10

Diasorin receives FDA clearance for Simplexa VZV Swab Direct Molecular assay (571.47 KB)
Products Molecular

06/12/19 - 18:12

Press Release (262.61 KB)
Other

06/12/19 - 18:11

Press Release (262.7 KB)
Other

06/12/19 - 18:08

Communication on total amount of voting rights (281.87 KB)
Other

27/11/19 - 7:59

DIASORIN LAUNCHES THE LIAISON QUANTIFERON-TB GOLD PLUS ASSAY IN PARTNERSHIP WITH QIAGEN IN THE US MARKET (531.97 KB)
Products Immunodiagnostic

11/11/19 - 9:46

DIASORIN LAUNCHES PRIMER PAIR FOR CANDIDA AURIS IN THE US MARKET (159.93 KB)
Products Molecular

06/11/19 - 13:00

Record free cash flow generation along with growth in revenues and profitability for DiaSorin in the first 9 months of 2019 (621.09 KB)
Financial Data

30/10/19 - 9:55

DIASORIN LAUNCHES LIAISON® XL ZIKA CAPTURE IgM II TEST FOR THE DETECTION OF ZIKA VIRUS IN THE US MARKET (579.27 KB)
Products Immunodiagnostic

22/10/19 - 14:10

DIASORIN LAUNCHES LIAISON HCV TEST FOR HEPATITIS C DIAGNOSIS IN THE US MARKET (358.37 KB)
Products Immunodiagnostic

07/10/19 - 10:20

Communication on total amount of voting rights (282.21 KB)
Other

24/09/19 - 10:10

DiaSorin launches VZV Direct molecular test in Europe (369.67 KB)
Products Molecular

31/07/19 - 13:00

DiaSorin Board of Directors approves first half 2019 results. Growth in revenues and profitability. (687.57 KB)
Financial Data

10/06/19 - 18:23

DiaSorin presents its 2019-2022 Industrial Plan (548.2 KB)
Financial Data

05/06/19 - 7:38

DiaSorin and QIAGEN collaborate on novel QuantiFERON-based test with breakthrough potential for earlier detection of Lyme disease (448.98 KB)
Acquisition / Partnership Immunodiagnostic

29/05/19 - 15:06

DiaSorin launches VZV DIRECT molecular test in the United States (360.87 KB)
Products Molecular

09/05/19 - 13:14

DiaSorin Group reports growth in profitability and strong free cash flow generation in the first quarter 2019 (728.82 KB)
Financial Data

06/05/19 - 15:19

DiaSorin launches ELASTASE-1 test for the diagnosis of chronic exocrine pancreatitis on LIAISON XL (416.77 KB)
Products Immunodiagnostic

30/04/19 - 12:28

Update Annual Calendar of Corporate Events 2019 (249.43 KB)
Other

24/04/19 - 17:24

DiaSorin: Shareholders' Meeting 2019 (449.66 KB)
Other

12/04/19 - 8:59

Communication on total amount of voting rights (320.44 KB)
Other

05/04/19 - 9:33

Communication on total amount of voting rights (342.47 KB)
Other

03/04/19 - 20:18

Lists publication (79.68 KB)
Other

03/04/19 - 10:32

DiaSorin launches the anaemia panel on Liaison XL in Europe (416.47 KB)
Products Immunodiagnostic

14/03/19 - 14:16

Growth in revenues, profitability and net profit in 2018 (1.03 MB)
Financial Data

07/03/19 - 11:45

Communication on total amount of voting rights (350.08 KB)
Other

06/03/19 - 8:45

A new Group website for DiaSorin: www.diasoringroup.com (154.5 KB)
Other

07/02/19 - 15:15

Communication on total amount of voting rights (February 7, 2019) (349.86 KB)
Other

31/01/19 - 22:30

DiaSorin launches FDA-cleared LIAISON Calprotectin test in the US market (528.02 KB)
Products Immunodiagnostic

03/01/19 - 13:30

DiaSorin launches Simplexa Bordetella Direct Molecular test in the United States (428.56 KB)
Products Molecular